25.07.2014 • News

Merck Serono Extends Italian Alliance for Neurodegenerative Diseases

Merck Serono, the biopharmaceuticals arm of Germany's Merck KgaA, is extending by two years its 10-year R&D cooperation with San Raffaele University & Research Hospital for Research in Milan focusing on neurodegenerative diseases.

The partners are aiming at the development of pre-clinical and clinical research projects with a focus on developing innovative therapies against serious and disabling neurological diseases such as multiple sclerosis affecting young adults in particular.

San Raffaele University & Research Hospital are providing know-how and laboratories to develop new therapies and to evaluate the effectiveness of the molecules developed by Merck Serono.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.